Prognostic factors for risk-adapted therapy in chronic lymphocytic leukemia - the search continues

Leuk Lymphoma. 2007 Aug;48(8):1468-9. doi: 10.1080/10428190701534473.

Authors

Yair Herishanu¹, Adrian Wiestner

Affiliation

¹ Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1202, USA.

PMID: 17701575
DOI: 10.1080/10428190701534473

No abstract available

Publication types

Comment

MeSH terms

ADP-ribosyl Cyclase 1 / metabolism
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
Biomarkers, Tumor / metabolism*
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
Membrane Glycoproteins / metabolism
Prognosis
ZAP-70 Protein-Tyrosine Kinase / metabolism

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1
Biomarkers, Tumor
Membrane Glycoproteins
ZAP-70 Protein-Tyrosine Kinase
ZAP70 protein, human
CD38 protein, human
ADP-ribosyl Cyclase 1